BioSpace

Milestone Sanfilippo nod helps Ultragenyx regroup after tough Angelman defeat

The recent FDA approval of Fayuvi for a rare, childhood neurodegenerative disease was “particularly special” for Ultragenyx CEO Emil Kakkis. It could also, along with an August nod for another gene therapy, help offset recent challenges brought on by two asset failures.

Por BioSpace

1 minuto de lectura
Compartir
Milestone Sanfilippo nod helps Ultragenyx regroup after tough Angelman defeat
Milestone Sanfilippo nod helps Ultragenyx regroup after tough Angelman defeat

¿Tiene noticias que compartir con el sector de eventos?

Envíe un comunicado de prensa o una noticia y llegue a miles de profesionales del sector de eventos.

Contáctenos→

Más en Health Tech

Perspectivas relacionadas